Introduction {#s1}
============

A key component of the directly observed treatment short-course (DOTS) strategy of the World Health Organization (WHO) is the use of a limited number of standardized regimens [@pmed.1000150-World1]. This strategy ensures that treatment is always given with the same number, dose, and type of medications---the simplicity enhances access to treatment in resource-poor settings. A single 8-mo "retreatment" regimen (8 mo of isoniazid, rifampin, ethambutol, with pyrazinamide added for the first 3 mo, and streptomycin added for the first 2 mo---2SHRZE/1HRZE/5HRE) is recommended for all patients with a history of previous treatment [@pmed.1000150-World1] and is used in more than 90 countries [@pmed.1000150-Mak1].

This WHO retreatment regimen was initially designed for resource-poor settings with low prevalence of initial drug resistance, and for patients previously treated with a regimen that used rifampin only for the first 2 mo of therapy [@pmed.1000150-Rouillon1]. It was believed that the regimen should be adequate for patients with mono-resistance, such as to isoniazid. However, this regimen has been increasingly criticized [@pmed.1000150-Espinal1],[@pmed.1000150-Espinal2] because of poor results [@pmed.1000150-Mak1], particularly in settings where prevalence of initial drug resistance is high [@pmed.1000150-Mak1],[@pmed.1000150-Kimerling1] or rifampin is used throughout initial therapy [@pmed.1000150-Becerra1]. In light of these concerns, we have conducted a systematic review of published evidence of treatment of patients with a history of previous treatment or documented isoniazid mono-resistance.

Review Questions {#s2}
================

Our systematic review addressed two specific questions:

1.  What are the rates of failure, relapse, and acquired drug resistance with the currently recommended WHO retreatment regimen---in randomized trials and cohort studies?

2.  What treatment factors are associated with failure, relapse, and acquired drug resistance in randomized trials of patients with pretreatment resistance to isoniazid?

Methods {#s3}
=======

Search Strategy {#s3a}
---------------

As seen in [Figure 1](#pmed-1000150-g001){ref-type="fig"}, we searched three electronic databases---PubMed, EMBASE, and the Cochrane Central database---for randomized controlled trials (RCTs) of treatment of patients with previous TB treatment, or mono-resistance to isoniazid. The search was restricted to studies published in English, French, or Spanish between 1965 and June 2008. Our keywords included tuberculosis or TB, retreatment or repeated therapy or previously treated patients, and failure or relapse or drug resistance. To identify additional relevant articles, we searched reference lists of identified original articles, recent reviews [@pmed.1000150-Fox1], chapters from texts [@pmed.1000150-Rieder1],[@pmed.1000150-Hopewell1], and recent treatment guidelines [@pmed.1000150-World1],[@pmed.1000150-Long1],[@pmed.1000150-American1].

![Summary of study review and selection.](pmed.1000150.g001){#pmed-1000150-g001}

Study Selection {#s3b}
---------------

In selected studies, all patients had bacteriologically confirmed (by smear and/or culture) active pulmonary TB, and reported treatment outcomes of bacteriologically confirmed failure and/or relapse. Treatment was standardized and included at least rifampin. We excluded studies or arms that utilized rifapentine, rifabutin, or nondrug therapy (for example, immunotherapeutic vaccines). We also excluded regimens with once weekly or single drug therapy, as these would now be considered inadequate [@pmed.1000150-Long1]--[@pmed.1000150-Enarson1].

The selection of articles for review was done independently by two investigators in three stages: titles alone, then abstracts, and then full text articles. Decisions were compared and disagreements about study selection were resolved by consensus or by involving a third reviewer. We initially planned to select only RCTs in previously treated patients. We could not identify any randomized trial that evaluated specifically the current WHO retreatment regimen (2SHRZE/1HRZE/5HRE). Therefore, we included any cohort studies that used this specific regimen, reported individual outcomes, and met all inclusion criteria above.

We found only 11 randomized trials in previously treated patients, of which nine evaluated patients with isoniazid mono-resistance (these trials used several different regimens, but all different from the WHO retreatment regimen). Therefore, we decided to include trials, identified in a separate systematic review, in which previously untreated patients with mono-resistance to isoniazid were treated with standardized rifampin containing regimens. (For methods, see Menzies et al. [@pmed.1000150-Menzies1].)

Data Extraction and Quality Assessment {#s3c}
--------------------------------------

We used standardized forms to extract data from selected studies about patient population and characteristics, treatment regimen, and pretreatment drug-susceptibility testing---if done, supervision of treatment, funding source, and number of patients who started treatment, died, failed, relapsed, defaulted, or were otherwise lost. Two reviewers extracted the data, with disagreements resolved by consensus.

The selection criteria requiring microbiologic confirmation of initial diagnosis and treatment outcomes meant that selected studies had high-quality diagnostic methods. Another indicator of study quality was the number of patients who refused therapy, dropped out, moved away, or were otherwise unaccounted for during therapy. Trials were considered to have high-quality methods of randomization if they used central randomization, numbered opaque sealed envelopes, sealed envelopes from a closed bag, or numbered or coded bottles or containers.

Outcomes {#s3d}
--------

Treatment failure was defined as sputum smears and/or cultures that were consistently positive or positive requiring treatment after at least 5 mo of therapy [@pmed.1000150-World2]. Relapse was defined as recurrence of positive smears and/or cultures that required therapy 1 mo or more after apparent cure [@pmed.1000150-World2]. Acquired drug resistance was defined as new or additional resistance to one or more of the TB drugs received---in the setting of failure or relapse. Patients with pretreatment rifampin resistance, including multidrug resistance, were excluded from analysis, if identified in the published report.

Data Synthesis and Analysis {#s3e}
---------------------------

We were interested to understand the efficacy of different regimens in preventing failure, relapse, and acquired drug resistance---end-points with objective microbiological definitions that were consistent across trials. Therefore, we used a per-protocol analysis, excluding patients who did not complete therapy because they developed serious adverse reactions, died, defaulted, dropped out, or were otherwise not accounted for.

Only 6 cohort studies were found that evaluated the current WHO retreatment regimen; these results were not pooled. Of 11 trials in previously treated patients, nine included patients with mono-resistance to isoniazid, one included patients only with poly-drug resistant strains [@pmed.1000150-Nitti1], while another, which included patients with multiple forms of resistance, did not report results by type of drug resistance [@pmed.1000150-Salinger1]. Results from the last two trials were not analyzed. To increase power, results from the nine trials in isoniazid mono-resistant previously treated patients were pooled with results of the subgroups of patients with mono-isoniazid resistance in 24 trials in new cases.

Very few trials with head-to-head comparisons were identified, and no two trials made the same comparisons. Hence we pooled results across all trials, effectively treating each arm within each trial as an independent cohort. For this across-trial analysis, we used a random effects meta-analysis to estimate the overall pooled estimates of cumulative incidence and 95% CI of failure, relapse, and acquired drug resistance using PROC NLMIXED in SAS (SAS institute, Carey, NC, USA) [@pmed.1000150-Hamza1]. We used the exact binomial likelihood approach [@pmed.1000150-Hamza1], which uses a binomial distribution to approximate the distribution of the outcome of interest. This approach accounts for study size and includes a random effect to account for inter-study heterogeneity. When proportions are the outcome measure, this approach has been demonstrated to produce less-biased estimates of the pooled effect and the between-study variability [@pmed.1000150-Hamza1]. To minimize heterogeneity, we performed subgroup analyses stratified by predefined covariates of interest. These included the following characteristics of the re-treatment regimen duration and dosing schedule of rifampin, initial drug resistance, use of pyrazinamide or streptomycin, and number of drugs to which the organism was susceptible used in the initial or continuation phase (the initial intensive phase was defined as the initial period when more drugs were used---usually the first 1--2 mo---while the continuation phase was the remainder of therapy). We also examined the effect of supervision of therapy, proportion that were smear positive, and default or other losses during treatment phase follow-up. We assessed heterogeneity of outcomes of interest, within subgroups defined by covariates of interest by estimating the I^2^ statistic and associated 95% CIs [@pmed.1000150-Higgin1].

Finally, meta-regression was used to estimate the effect of the treatment factors of interest, after adjustment for other potentially confounding patient and treatment covariates. Because the outcomes we were pooling were proportions, rather than odds ratios, and because these proportions were usually small, we performed meta-regression using the Poisson model [@pmed.1000150-Glasziou1] that allowed for overdispersion (i.e., negative binomial regression). In this meta-regression, each arm in each study was the unit of analysis, cumulative incidence of TB treatment outcomes was the dependent variable, and TB treatment characteristics were the independent variables. An offset was used to account for size of study. In this approach, residual heterogeneity between studies is accounted for in the dispersion parameter. As such, we interpreted the dispersion parameter as indicating there was no remaining unexplained heterogeneity if the value was not significantly different from 0, and as minimal heterogeneity if the value was less than 1.0 [@pmed.1000150-Thompson1]. Effect estimates of the meta-regression model were interpreted as adjusted incidence rate ratios [@pmed.1000150-Glasziou1]. We tested the significance of each factor in the models using the likelihood ratio test.

The final model included rifampin duration, intermittent schedule, use of pyrazinamide and streptomycin, number of drugs in initial or continuation phases to which organisms were susceptible, length of follow-up after end of treatment (for relapse and acquired drug resistance), supervision of therapy (directly observed therapy \[DOT\]), and noncompletion of therapy because of protocol violations, patient refusal, default, moved, or lost.

Results {#s4}
=======

Study Selection {#s4a}
---------------

As seen in [Figure 1](#pmed-1000150-g001){ref-type="fig"}, 1,464 citations were identified from the search of the three electronic databases. Of these, 147 were retained for abstract review and 96 for full text review. In total, six cohort studies were found describing results with the standardized 8-mo retreatment in previously treated patients with pretreatment drug susceptibility testing (DST) [@pmed.1000150-Kimerling1],[@pmed.1000150-Churchyard1]--[@pmed.1000150-Pardeshi1], and 12 reports describing nine randomized trials in previously treated patients with isoniazid mono-resistance [@pmed.1000150-Babu1]--[@pmed.1000150-Zierski2]. To these, we added results in previously untreated patients with initial mono-resistance to isoniazid taken from 38 published reports describing 24 randomized trials [@pmed.1000150-Singapore1]--[@pmed.1000150-Hong12]. The initial diagnosis and outcomes were confirmed with cultures (i.e., not just smears) in all randomized trials. In the trials, rifampin dose was 600 mg (or 10--12 mg/kg) in all trials except three trials that used 450 mg daily [@pmed.1000150-Tuberculosis1],[@pmed.1000150-Aziz1],[@pmed.1000150-Hong11], one that used 450 mg daily followed by 600 mg thrice weekly [@pmed.1000150-Hong2], and one with 450 mg daily followed by 900 mg twice weekly [@pmed.1000150-Hong1]. Other characteristics of the studies and study populations are summarized in [Table S1](#pmed.1000150.s002){ref-type="supplementary-material"}.

Results from Cohort Studies with Standardized WHO Retreatment Regimen {#s4b}
---------------------------------------------------------------------

As shown in [Table 1](#pmed-1000150-t001){ref-type="table"}, failure rates were low in most cohorts with pan-sensitive strains that received the standardized retreatment regimen, although the rate was inexplicably high in one study [@pmed.1000150-Espinal3]. In cohorts with mono-resistance to isoniazid, failure rates ranged from 18%--44%, compared to 9%--45% in cohorts whose drug resistance patterns were not reported. Pooled estimates were not calculated because of heterogeneity in results.

10.1371/journal.pmed.1000150.t001

###### Cohort studies reporting results with standardized retreatment regimen recommended by WHO.

![](pmed.1000150.t001){#pmed-1000150-t001-1}

  ID                                                           Reference            Regimen[a](#nt102){ref-type="table-fn"}   Total Number Treated   Number at Risk for Failure[b](#nt103){ref-type="table-fn"}   Number (%) Who Failed   Number at Risk for Acquired Drug Resistance[c](#nt104){ref-type="table-fn"}   Number with Acquired Drug Resistance
  -------------------------------------------------- ----------------------------- ----------------------------------------- ---------------------- ------------------------------------------------------------ ----------------------- ----------------------------------------------------------------------------- --------------------------------------
  **Pan-sensitive strains**                                                                                                                                                                                                                                                                                            
  33                                                  [@pmed.1000150-Churchyard1]              2HRZES/1HRZE/5HRE                      382                                       306                                     2 (0.7%)                                              306                                                        1
  34                                                    [@pmed.1000150-Sevim1]                 2HRZES/1HRZE/5HRE                       30                                        28                                         0                                                 28                                                         0
  340                                                  [@pmed.1000150-Espinal3]                2HRZES/1HRZE/5HRE                      122                                        87                                      5 (6%)                                               ---                                                       ---
                                                                                           2HRZES/1HRZE/5\[HRE\]~2~                   260                                       208                                      13 (6%)                                              ---                                                       ---
                                                                                           2HRZES/1HRZE/5\[HRE\]~3~                   104                                        64                                     17 (27%)                                              ---                                                       ---
  **Mono-resistance to INH**                                                                                                                                                                                                                                                                                           
  340                                                  [@pmed.1000150-Espinal3]                2HRZES/1HRZE/5HRE                       57                                        39                                      7 (18%)                                              ---                                                       ---
                                                                                           2HRZES/1HRZE/5\[HRE\]~2~                    37                                        31                                      6 (19%)                                              ---                                                       ---
                                                                                           2HRZES/1HRZE/5\[HRE\]~3~                    30                                        18                                      8 (44%)                                              ---                                                       ---
  **Mixed drug resistance (all forms or unknown)**                                                                                                                                                                                                                                                                     
  324                                                   [@pmed.1000150-Santha1]     2\[HRZES\]~3~/1\[HRZE\]~3~/5\[HRE\]~3~             57                                        46                                      4 (9%)                                               ---                                                       ---
                                                                                    2\[HRZES\]~3~/2\[HRZE\]~3~/5\[HRE\]~3~             17                                        11                                      5 45%)                                               ---                                                       ---
  384                                                 [@pmed.1000150-Kimerling1]               2HRZES/1HRZE/5EHR                      210                                       183                                     47 (26%)                                              ---                                                       ---
  415                                                  [@pmed.1000150-Pardeshi1]    2\[HRZES\]~3~/1\[HRZE\]~3~/5\[HRE\]~3~            507                                       389                                     52 (13%)                                              ---                                                       ---

None of these studies ascertained relapse after treatment completion.

Regimen abbreviations: H, isoniazid; R, rifampin; Z, pyrazinamide; E, ethambutol; S, streptomycin. Letters to left of "/" indicate regimen in initial intensive phase; letters to right of "/" indicate regimen in continuation phase. First number signifies the months of initial phase of treatment and the second number signifies the months of continuation phase treatment. \[ \] indicate intermittent therapy; subscript number after \[ \] indicates number of doses per week.

Number at risk for failure excluded those who died, defaulted, or had serious adverse reactions during therapy (i.e., included only those who completed treatment or failed).

If acquired drug resistance was not measured, this is indicated as "---".

Results from RCTs in Previously Treated Patients with INH Mono-resistance {#s4c}
-------------------------------------------------------------------------

In the nine randomized trials, summarized in [Table 2](#pmed-1000150-t002){ref-type="table"}, randomization was high quality in eight, and treatment phase losses were less than 10% in six. Regimens and treatment outcomes varied widely. In three studies that used the standard therapy for drug-sensitive TB of 2HRZ (±E)/4HR [@pmed.1000150-Narayanan1],[@pmed.1000150-Tuberculosis1],[@pmed.1000150-Castelo1], the combined failure and relapse rates ranged from 29%--70%. In four studies [@pmed.1000150-National1],[@pmed.1000150-Hong1],[@pmed.1000150-Hong2]--[@pmed.1000150-Zierski2] in which patients were given rifampin plus ethambutol for 12 mo or more, failure rates ranged from 4%--23% and relapse rates from 0%--27%. The regimen most like the current retreatment regimen was evaluated in a single trial [@pmed.1000150-Babu1]. A total of 179 evaluable patients received 2SRZE/4RE or 2SRZE/7RE with failure and relapse rates of 1% and 3%, respectively [@pmed.1000150-Babu1]. In one arm of one trial, among 89 patients who received a similar regimen of 3REZ/9RE (albeit thrice weekly), failure and relapse rates were 23% and 20%, respectively [@pmed.1000150-Hong2].

10.1371/journal.pmed.1000150.t002

###### Regimens and results in randomized trials in previously treated patients with INH mono-resistance.

![](pmed.1000150.t002){#pmed-1000150-t002-2}

  ID                                                   Reference                                                        Regimen[a](#nt106){ref-type="table-fn"}          Total Number Treated   At Risk for Failure (*N*)[b](#nt107){ref-type="table-fn"}   Number (%) who Failed   At Risk for Relapse (*N*)[c](#nt108){ref-type="table-fn"}   Number (%) who Relapsed   At Risk for Acquired Drug Resistance (*N*)[b](#nt107){ref-type="table-fn"}   Number (%) with Acquired Drug Resistance
  ----- ------------------------------------------------------------------------------------------------------- ------------------------------------------------------- ---------------------- ----------------------------------------------------------- ----------------------- ----------------------------------------------------------- ------------------------- ---------------------------------------------------------------------------- ------------------------------------------
  14                                             [@pmed.1000150-Babu1]                                                                 2SZRE/4RE                                 101                                       91                                         0                                        72                                       3 (4%)                                                91                                                          0
                                                                                                                                       2SZRE/7RE                                  97                                       88                                      1 (1%)                                      72                                       2 (3%)                                                88                                                          0
  23                                          [@pmed.1000150-Narayanan1]                                                        2\[HRZE\]~3~/4\[HR\]~2~                          171                                       167                                    32 (19%)                                     135                                     14 (10%)                                              167                                                       23 (14%)
  50                                         [@pmed.1000150-Tuberculosis1]                                                             2HRZE/6EH                                 101                                       94                                     16 (17%)                                     73                                       6 (8%)                                                94                                                        3 (3%)
                                                                                                                               2\[HRZE\]~2~/4\[HRE\]~2~                           63                                       59                                     12 (20%)                                     44                                      11 (25%)                                               59                                                       7 (12%)
                                                                                                                                2\[HRZ\]~2~/4\[HR\]~2~                            79                                       74                                     46 (62%)                                     27                                       4 (15%)                                               74                                                       13 (18%)
  302                                            [@pmed.1000150-Hong2]                                                **Subgroup with isoniazid mono-resistance**                                                                                                                                                                                                                                                                                     
                                                                                                                                   12RE *(RIF 450)*                               83                                       73                                     20 (27%)                                     19                                       5 (26%)                                               73                                                       19 (26%)
                                                                                                                                12\[RE\]~3~ *(RIF 450)*                           91                                       75                                     22 (29%)                                     22                                       6 (27%)                                               75                                                       21 (28%)
                                                                                                                          3\[REZ\]~3~/9\[RE\]~3~ *(RIF 450)*                      89                                       77                                     18 (23%)                                     30                                       6 (20%)                                               77                                                       17 (22%)
                                                                                                                           3\[RE\]~3~/9\[RE\]~3~ *(RIF 450)*                      94                                       75                                     10 (13%)                                     35                                      12 (34%)                                               75                                                       10 (13%)
  302                                            [@pmed.1000150-Hong2]                                           **Subgroup with isoniazid and ethambutol resistance**                                                                                                                                                                                                                                                                                
                                                                                                                                   12RE *(RIF 450)*                               25                                       15                                     10 (67%)                                      5                                       1 (20%)                                              ---                                                         ---
                                                                                                                                12\[RE\]~3~ *(RIF 450)*                           22                                       12                                      8 (67%)                                      4                                       1 (25%)                                              ---                                                         ---
                                                                                                                          3\[REZ\]~3~/9\[RE\]~3~ *(RIF 450)*                      20                                       12                                      5 (42%)                                      7                                          0                                                 ---                                                         ---
                                                                                                                          3\[REPt\]~3~/9\[RE\]~3~ *(RIF 450)*                     16                                        6                                      2 (33%)                                      4                                       1 (25%)                                              ---                                                         ---
  326                                            [@pmed.1000150-Hong1]                                                             12ER *(RIF 450)*                              112                                       106                                    11 (10%)                                     ---                                        ---                                                106                                                        9 (8%)
                                                                                                                                12\[ER\]~2~ *(RIF 450)*                           93                                       87                                     16 (18%)                                     ---                                        ---                                                 87                                                       15 (17%)
  328                                          [@pmed.1000150-Castelo1]                                                                2HRZ/4HR                                   9                                         9                                      3 (33%)                                      6                                       1 (17%)                                               6                                                           0
                                                                                                                                     2HRZ/4(HR)~2~                                4                                         4                                      1 (25%)                                      3                                          0                                                  3                                                           0
  357                                            [@pmed.1000150-Aziz1]                                                                   6HRZ                                     9                                         9                                         0                                        ---                                        ---                                                ---                                                         ---
                                                                                                                                         6HRE                                     10                                       10                                      5 (50%)                                     ---                                        ---                                                ---                                                         ---
                                                                                                                                         6HRZ                                     15                                        9                                         0                                        ---                                        ---                                                ---                                                         ---
                                                                                                                                         6HRE                                     15                                       10                                      5 (50%)                                     ---                                        ---                                                ---                                                         ---
  400    [@pmed.1000150-National1],[@pmed.1000150-National2],[@pmed.1000150-Zierski1],[@pmed.1000150-Zierski2]                      3RE/9\[RE\]~2~                                43                                       40                                      2 (5%)                                      38                                       2 (5%)                                               ---                                                         ---
                                                                                                                              3RE/9\[RE\]~2~ *(RIF 1200)*                         42                                       39                                      2 (5%)                                      37                                          0                                                 ---                                                         ---
                                                                                                                             3RE/15\[RE\]~2~ *(RIF 1200)*                         43                                       40                                      1 (3%)                                      40                                       2 (5%)                                               ---                                                         ---
                                                                                                                             3RE/21\[RE\]~2~ *(RIF 1200)*                         42                                       39                                      1 (3%)                                      38                                          0                                                 ---                                                         ---
  416                                         [@pmed.1000150-Sriyabhaya1]                                                         1.5RE/10.5\[RE\]~3~                             34                                       30                                      2 (7%)                                      23                                          0                                                 ---                                                         ---
                                                                                                                                      12\[RE\]~3~                                 38                                       33                                      4 (12%)                                     25                                          0                                                 ---                                                         ---

Dose of rifampin = 600 mg daily unless indicated otherwise.

Regimen abbreviations: H, isoniazid; R, rifampin; Z, pyrazinamide; E, ethambutol; S, streptomycin. Letters to left of "/" indicate regimen in initial intensive phase; letters to right of "/" indicate regimen in continuation phase. First number signifies the months of initial phase of treatment and the second number signifies the months of continuation phase treatment. \[ \] indicate intermittent therapy; subscript number after \[ \] indicates number of doses per week.

Number at risk for failure, relapse, or acquired drug resistance excluded those who died, defaulted, or had serious adverse reactions during therapy (i.e., included only those who completed treatment or failed).

If relapse or acquired drug resistance not measured, it is indicated as "---".

Pooled Results for Isoniazid Mono-resistance from All Trials {#s4d}
------------------------------------------------------------

In the 24 randomized trials in new cases, randomization was high quality in 16, but not specified in eight, and treatment phase losses were less than 10% in 18 (67%). In the total of 33 trials with patients with isoniazid mono-resistance, treatment failure was assessed in 1,907 patients within 101 different treatment arms, relapse in 1,196 persons in 93 arms, and acquired drug resistance was assessed in 1,484 patients in 76 different arms. As seen in [Table 3](#pmed-1000150-t003){ref-type="table"}, failure was significantly lower if streptomycin was used, or if a larger number of effective drugs were used in the initial or continuation phases. Failure rates progressively fell with longer use of pyrazinamide, although all CIs overlapped. There was also a trend for higher failure rates if rifampin was used for only 2 mo, or drugs were administered biweekly throughout therapy. Results were very similar when the analysis was restricted to high-quality studies---in which less than 10% of participants dropped out, moved, or were otherwise lost to follow-up during the treatment phase.

10.1371/journal.pmed.1000150.t003

###### Stratified analysis of covariates associated with TB treatment outcomes in RCT of patients with INH resistance in new or previously treated cases: Failure in isoniazid mono-resistance.

![](pmed.1000150.t003){#pmed-1000150-t003-3}

  Factor                                                                                      Arms (*N*)   Events/Patients (*N*)   Pooled Event Rate      95% CI         I^2^ (95% CI)
  ------------------------------------------------------------------------------------------ ------------ ----------------------- ------------------- --------------- -------------------
  **Rifampin use**                                                                                                                                                    
  Rifampin 1--2 mo                                                                                19              30/256                  6.2             0--12.8         0 (0--0.48)
  Rifampin 3--5 mo                                                                                10               2/88                   0.9             0--2.9          0 (0--0.60)
  Rifampin 6--7 mo                                                                                46              108/645                 4.8            0.8--8.8      0.76 (0.69--0.82)
  Rifampin 8+ mo                                                                                  19              136/858                 7.4             0--15.1      0.87 (0.82--0.91)
  **Frequency of therapy in the initial intensive phase** [a](#nt110){ref-type="table-fn"}                                                                            
  Daily                                                                                           65             99/1,062                 5.1            2.2--8.0      0.50 (0.33--0.62)
  Thrice weekly                                                                                   25              102/559                 5.2             0--10.5      0.44 (0.10--0.65)
  Twice weekly                                                                                    4               75/226                 25.5             0--52.8      0.93 (0.86--0.97)
  **Duration of PZA**                                                                                                                                                 
  No PZA                                                                                          28              123/769              **11.4**        **4.0--18.8**   0.74 (0.63, 0.82)
  1--3 mo                                                                                         39              147/871                 6.6            2.3--10.9     0.83 (0.77--0.87)
  4 mo or more                                                                                    27               6/207                  1.7             0--3.6          0 (0--0.42)
  **Duration of streptomycin**                                                                                                                                        
  No streptomycin                                                                                 43             258/1,294             **13.6**        **7.8--19.3**   0.80 (0.73--0.85)
  1--3 mo                                                                                         28              13/383                  2.8            0.6--5.0         0 (0--0.41)
  4 mo or more                                                                                    23               5/170                  2.1             0--4.5          0 (0--0.46)
  **Number of drugs to which strains susceptible (effective drugs)**                                                                                                  
  ***Initial phase*** [b](#nt111){ref-type="table-fn"}                                                                                                                
  1 drugs                                                                                         3                22/39               **50.8**        **6.1--9.6**     0.52 (0--0.86)
  2 drugs                                                                                         31              99/628                 11.3             0.3--19      0.58 (0.37--0.72)
  3 drugs                                                                                         55              148/932                 3.8            0.9--6.7      0.58 (0.43--0.69)
  4 or more drugs                                                                                 3                1/185                  0.4             0--1.5          0 (0--0.73)
  ***Continuation phase***                                                                                                                                            
  0--1 drugs                                                                                      44              153/688               **9.1**        **3.0--15.2**   0.71 (0.61--0.79)
  2 drugs                                                                                         35              116/998               **6.0**        **1.6--10.5**   0.72 (0.61--0.80)
  3 or more drugs                                                                                 11               1/92                   0.5             0--1.6          0 (0--0.58)
  **Supervision of therapy**                                                                                                                                          
  All doses fully supervised                                                                      69             148/1,341                3.8            1.2--6.3      0.59 (0.46--0.68)
  None/partial supervision                                                                        25              128/506                13.8            4.7--22.8     0.80 (0.71--0.86)
  **Completion of treatment**                                                                                                                                         
  ≥90%                                                                                            55             187/1,353                6.0            2.0--9.9      0.78 (0.71--0.83)
  \<90%                                                                                           39              89/494                  6.5            0.7--12.4     0.50 (0.28--0.66)

Event rate and 95% CI are **in bold** if CIs for two or more strata do not overlap.

In all but one trial, if therapy was intermittent initially the same schedule was continued throughout therapy. In trials where therapy was daily initially, it was given daily, thrice, or twice weekly thereafter, but outcomes were not different, so these regimens were considered equivalent.

In a few trials, the number of drugs was the same throughout---these were classified according to the starting regimen.

As shown in [Figure S1A](#pmed.1000150.s001){ref-type="supplementary-material"}, the pooled relapse rate was 10% in the randomized trials of patients with INH resistance, compared to 15% in the subgroup with INH resistance in randomized trials of new cases ([Figure S1B](#pmed.1000150.s001){ref-type="supplementary-material"}), with substantial variation in rates in different studies. As shown in [Table 4](#pmed-1000150-t004){ref-type="table"}, relapse rates were significantly higher if rifampin was used for only 2 mo. Nonsignificant but potentially important differences in relapse rates were seen with biweekly dosing schedules in the initial intensive phase, and with fewer effective drugs in the initial intensive phase. As shown in [Table 5](#pmed-1000150-t005){ref-type="table"}, acquired drug resistance (i.e., amplification of drug resistance) was significantly lower with use of streptomycin or a greater number of effective drugs in the initial intensive phase. As with failure, acquired drug resistance was progressively less frequent with longer use of pyrazinamide, although all CIs overlapped. Death during treatment was not analyzed as a primary outcome because most studies did not report the timing of death, and early or late deaths during treatment may have very different risk factors. Mortality during treatment was higher in patients treated with regimens for 1 y or longer (unpublished data). After accounting for this, death during treatment was not associated with any other treatment characteristic (unpublished data).

10.1371/journal.pmed.1000150.t004

###### Stratified analysis of covariates associated with TB treatment outcomes in RCT of patients with INH resistance in new or previously treated cases: Relapse in isoniazid mono-resistance.
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  Factor                                                                                      Arms (*N*)   Events/Patients (*N*)   Pooled Event Rate      (95% CI)          I^2^ (95% CI)
  ------------------------------------------------------------------------------------------ ------------ ----------------------- ------------------- ---------------- -----------------------
  **Rifampin use**                                                                                                                                                     
  Rifampin 1--2 mo                                                                                18              43/196               **23.8**        **11.6--36.0**   **0.44 (0.02--0.68)**
  Rifampin 3--5 mo                                                                                10               10/83                  9.2            0.9--17.5           0 (0--0.60)
  Rifampin 6--7 mo                                                                                43              46/479                  7.1            3.4--10.9           0 (0--0.35)
  Rifampin 8+ mo                                                                                  17              38/409                  4.6             0.6--8.6        0.58 (0.29--0.76)
  **Frequency of therapy in the initial intensive phase** [a](#nt113){ref-type="table-fn"}                                                                             
  Daily throughout                                                                                60              76/738                  9.3            5.2--13.5         0.25 (0--0.47)
  Thrice weekly throughout                                                                        25              46/353                  7.3            1.5--13.1         0.07 (0--0.39)
  Twice weekly throughout                                                                         3                15/76                 13.4             0--33.3            0 (0--0.73)
  **Duration of PZA**                                                                                                                                                  
  No PZA                                                                                          25              45/365                 10.9            3.6--18.2        0.53 (0.26--0.70)
  1--3 mo                                                                                         38              78/641                 10.1            5.1--15.2         0.28 (0--0.53)
  4 mo or more                                                                                    25              14/161                  6.4            1.4--11.3           0 (0--0.43)
  **Duration of streptomycin**                                                                                                                                         
  No streptomycin                                                                                 38              77/705                  7.5            3.3--11.7        0.41 (0.13--0.60)
  1--3 mo                                                                                         28              46/328                 13.2            6.4--20.0        0.43 (0.11--0.64)
  4 mo or more                                                                                    22              14/134                  6.9            1.1--12.8           0 (0--0.45)
  **Number of drugs to which strains susceptible (effective drugs)**                                                                                                   
  ***Initial phase*** [b](#nt114){ref-type="table-fn"}                                                                                                                 
  1 drugs                                                                                         3                3/17                  15.3             0--40.8            0 (0--0.73)
  2 drugs                                                                                         26              24/278                  7.7            1.2--14.1         0.11 (0--0.44)
  3 drugs                                                                                         54              105/675                12.2            6.2--18.2           0 (0--0.32)
  4 or more drugs                                                                                 3                5/149                  2.6              0--7.9            0 (0--0.73)
  ***Continuation phase***                                                                                                                                             
  0--1 drugs                                                                                      43              71/514                  9.3            4.0--14.5           0 (0--0.35)
  2 drugs                                                                                         30              55/516                 11.1            4.2--17.9        0.52 (0.28--0.69)
  3 or more drugs                                                                                 11               10/83                  8.0             0--16.7            0 (0--0.58)
  **Supervision of therapy**                                                                                                                                           
  All doses fully supervised                                                                      66              107/861                12.3            7.7--16.8        0.36 (0.14--0.53)
  None or partial supervision                                                                     22              30/306                  5.8            1.6--10.0           0 (0--0.46)
  **Completion of treatment**                                                                                                                                          
  ≥90%                                                                                            51              97/886                 11.1            6.5--15.7        0.40 (0.16--0.57)
  \<90%                                                                                           37              40/281                  8.2            3.1--13.3           0 (0--0.37)

Event rate and 95% CI are **in bold** if CIs for two or more strata do not overlap.

In all but one trial, if therapy was intermittent initially the same schedule was continued throughout therapy. In trials where therapy was daily initially, it was given daily, thrice, or twice weekly thereafter, but outcomes were not different, so these regimens were considered equivalent.

In a few trials, the number of drugs was the same throughout---these were classified according to the starting regimen.

10.1371/journal.pmed.1000150.t005

###### Stratified analysis of covariates associated with TB treatment outcomes in RCT of patients with INH resistance in new or previously treated cases: Acquired drug resistance in isoniazid mono-resistance.
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  Factor                                                                                      Arms (*N*)   Events/Patients (*N*)   Pooled Event Rate       (95% CI)          I^2^ (95% CI)
  ------------------------------------------------------------------------------------------ ------------ ----------------------- ------------------- ------------------- -------------------
  **Rifampin use**                                                                                                                                                        
  Rifampin 1--2 mo                                                                                17               6/222                  1.9               0--4.3            0 (0--0.50)
  Rifampin 3--5 mo                                                                                8                2/67                   2.0               0--5.8            0 (0--0.65)
  Rifampin 6--7 mo                                                                                39              51/580                  3.6              0.4--6.8        0.33 (0.01--0.55)
  Rifampin 8+ mo                                                                                  9               92/592                  7.4               0--15.7        0.91 (0.86--0.95)
  **Frequency of therapy in the initial intensive phase** [a](#nt116){ref-type="table-fn"}                                                                                
  Daily throughout                                                                                48              41/739                  2.8              0.7--4.9           0 (0--0.41)
  Thrice weekly throughout                                                                        21              74/496                  5.1               0--10.5           0 (0--0.46)
  Twice weekly throughout                                                                         4               36/226                 15.5               0--33.4           0 (0--0.77)
  **Duration of PZA**                                                                                                                                                     
  No PZA                                                                                          14              76/473                 10.0              1.2--18.8          0 (0--0.71)
  1--3 mo                                                                                         36              71/836                  3.7              0.8--6.6        0.55 (0.34--0.69)
  4 mo or more                                                                                    23               4/152                  1.2               0--3.1            0 (0--0.45)
  **Duration of streptomycin**                                                                                                                                            
  No streptomycin                                                                                 26              143/963              **12.5**        **7.6**--**17.3**   0.55 (0.30--0.71)
  1--3 mo                                                                                         25               6/347                  1.7              0.2--3.3           0 (0--0.43)
  4 mo or more                                                                                    22               2/151                  1.1               0--2.8            0 (0--0.45)
  **Number of drugs to which strains susceptible (effective drugs)**                                                                                                      
  ***Initial phase*** [b](#nt117){ref-type="table-fn"}                                                                                                                    
  0--1 drugs                                                                                      0                  0                    ---                 ---                 ---
  2 drugs                                                                                         21              72/415               **12.0**        **4.0**--**20.0**      0 (0--0.45)
  3 drugs                                                                                         49              79/861                  3.8              1.0--6.6           0 (0--0.33)
  4 or more drugs                                                                                 3                0/185                   0                0--1.4            0 (0--0.73)
  ***Continuation phase***                                                                                                                                                
  0--1 drugs                                                                                      35              56/589                  4.5              0.8--8.2           0 (0--0.38)
  2 drugs                                                                                         27              94/790                  4.9              0.5--9.2        0.76 (0.65--0.83)
  3 or more drugs                                                                                 9                1/76                   0.6               0--2.2            0 (0--0.62)
  **Supervision of therapy**                                                                                                                                              
  All doses fully supervised                                                                      57             103/1,089                3.1              0.7--5.5        0.51 (0.34--0.64)
  None or partial supervision                                                                     16              48/372                  7.8              0.7--15.0       0.48 (0.07--0.71)
  **Completion of treatment**                                                                                                                                             
  ≥90%                                                                                            42             96/1,071                 3.4              0.6--6.2         0.6 (0.4--0.8)
  \<90%                                                                                           31              55/390                  5.0              0.3--9.7           0 (0--0.40)

Event rate and 95% CI are **in bold** if CIs for two or more strata do not overlap.

In all but one trial, if therapy was intermittent initially the same schedule was continued throughout therapy. In trials where therapy was daily initially, it was given daily, thrice, or twice weekly thereafter, but outcomes were not different, so these regimens were considered equivalent.

In a few trials, the number of drugs was the same throughout---these were classified according to the starting regimen.

Meta-regression Results {#s4e}
-----------------------

In meta-regression ([Table 6](#pmed-1000150-t006){ref-type="table"}), patients with pretreatment isoniazid resistance had significantly worse treatment outcomes if therapy was intermittent (two or three times weekly) or included fewer effective drugs---in the initial intensive phase. Relapse was lower with longer duration of rifampin or pyrazinamide, but was not associated with duration of post-treatment follow-up. The 95% CI for the dispersion estimates for all three final models included 1, suggesting that the treatment factors included in these models accounted for the majority of the heterogeneity in outcomes seen.

10.1371/journal.pmed.1000150.t006

###### Adjusted incidence rate ratios of failure, relapse, and acquired drug resistance in INH resistant strains.
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  Factor                                                                    Failure               Relapse          Acquired Drug Resistance[a](#nt119){ref-type="table-fn"}
  ------------------------------------------------------------------ --------------------- ---------------------- ----------------------------------------------------------
  **Duration of rifampin therapy**                                                                                
  1--2 mo                                                             **4.1 (1.2--13.4)**    **3.8 (1.6--9.0)**                         0.7 (0.4--1.3)
  3--4 mo                                                               0.8 (0.2--5.0)         1.9 (0.7--5.2)                           1.0 (0.3--3.0)
  5--7 mo                                                               1.0 (reference)       1.0 (reference)                          1.0 (reference)
  ≥8 mo                                                                 1.6 (0.8--2.8)         1.0 (0.5--2.0)                           2.1 (0.9--4.9)
  Overall significance (*p*-value)[b](#nt120){ref-type="table-fn"}          (0.004)                (0.02)                                   (0.20)
  **Number of drugs in regimen to which strains sensitive**                                                       
  ***Initial intensive phase***                                                                                   
  0 or 1 drug                                                          **6.9 (1.4--33)**     **5.9 (1.0--33)**                             No obs.
  2 drugs                                                               2.7 (0.7--10.0)        1.9 (0.6--6.7)                          **18 (1.4--99)**
  3 drugs                                                               1.6 (0.4--6.0)         3.1 (0.9--9.9)                           9.6 (0.8--99)
  4 or more drugs                                                       1.0 (reference)       1.0 (reference)                          1.0 (reference)
  Overall significance (*p*-value)[b](#nt120){ref-type="table-fn"}          (0.06)                 (0.12)                                   (0.25)
  ***Continuation phase***                                                                                        
  0 or 1 drug                                                           2.5 (0.7--9.0)         1.0 (0.5--2.3)                           1.8 (0.5--6.5)
  2 drugs                                                               2.2 (0.6--8.5)         1.2 (0.7--2.5)                           1.2 (0.3--5.0)
  3 or more drugs                                                       1.0 (reference)       1.0 (reference)                          1.0 (reference)
  Overall significance (*p*-value)[b](#nt120){ref-type="table-fn"}          (0.36)                 (0.80)                                   (0.25)
  **Frequency of therapy**                                                                                        
  Initial daily                                                         1.0 (reference)       1.0 (reference)                          1.0 (reference)
  Thrice weekly throughout                                            **3.6 (1.6--7.7)**       2.1 (1.0--4.9)                           2.1 (0.9--4.5)
  Twice weekly throughout                                             **3.3 (1.8--6.2)**    **5.8 (1.8--18. 2)**                      **1.6 (1.1--2.3)**
  Overall significance (*p*-value)[b](#nt120){ref-type="table-fn"}         (0.0003)                (0.01)                                   (0.14)
  **Streptomycin**                                                                                                
  Not used                                                              1.0 (reference)       1.0 (reference)                          1.0 (reference)
  Used (2 wk or more)                                                 **0.4 (0.2--0.9)**       1.1 (0.5--2.2)                         **0.5 (0.2--1.0)**
  Overall significance (*p*-value)[b](#nt120){ref-type="table-fn"}          (0.007)                (0.80)                                  (0.003)
  **Pyrazinamide**                                                                                                
  Not used                                                              1.0 (reference)       1.0 (reference)                          1.0 (reference)
  Used (2 wk or more)                                                   1.2 (0.6--2.0)       **0.5 (0.2--1.0)**                         1.5 (0.9--2.3)
  Overall significance (*p*-value)[b](#nt120){ref-type="table-fn"}          (0.52)                 (0.05)                                   (0.15)

IRR, incidence rate ratios, from negative binomial regression. The percentage completing treatment, mean age, mean percentage male, mean percentage smear positive, and duration of post-treatment follow-up were not significantly associated with any of the three outcomes in preliminary models, so they were dropped from the final model. Incidence rate ratios and 95% CI are **in bold** if significantly different from reference group.

Acquired drug resistance in failures and/or relapses combined.

Significance of each factor in multivariate model from log likelihood ratio test.

Discussion {#s5}
==========

The most striking finding of this review is the remarkable lack of evidence in support of the WHO recommended retreatment regimen currently used to treat as many as one million TB patients every year [@pmed.1000150-Mak1]. The current body of evidence for treatment of previously treated patients is a dog\'s breakfast---a few cohort studies in patients with pretreatment drug sensitivity testing, a limited number of randomized trials in previously treated patients, and many small subgroups with initial drug resistance included in trials of new cases. Yet these are the only available results, and so must be extrapolated, albeit very cautiously, to the enormous challenge in resource-limited settings of treating the large number of patients, with a wide spectrum of drug resistance, who require retreatment.

This review is a reminder that, unlike the current initial treatment regimens, the current retreatment regimen was not tested and refined in a sequence of randomized trials. Instead, this regimen was the product of expert opinion [@pmed.1000150-Rouillon1]. Importantly, this was designed for settings with low prevalence of initial drug resistance and patients who had been treated with a regimen that included rifampin only for the first 2 mo [@pmed.1000150-Rouillon1]. In this situation, the regimen has high success rates [@pmed.1000150-Heldal1]. But treatment outcomes are much worse when used in settings with high initial drug resistance, for patients who previously received regimens with rifampin throughout [@pmed.1000150-Mak1],[@pmed.1000150-Kimerling1],[@pmed.1000150-Quy1].

The most important limitation of the review is also the most striking finding---the absence of published trials evaluating the current retreatment regimen and the remarkably small number of trials evaluating treatment in previously treated patients. None of these trials included HIV co-infected patients---limiting applicability of the findings to this important population. Because trials compared very different treatment regimens, we could not pool within-trial estimates of treatment effects, which could result in potential confounding. For example, virtually all intermittent therapy was wholly supervised; if intermittent therapy in the initial phase was inferior, this would make supervised therapy appear worse in stratified analysis. The across-trial analysis is also more questionable when outcomes are very heterogeneous. For example, failure and relapse rates differed considerably between the four trials, which evaluated apparently similar regimens of at least 12 mo of rifampin plus ethambutol [@pmed.1000150-National1],[@pmed.1000150-Hong1],[@pmed.1000150-Hong2]--[@pmed.1000150-Zierski2]. This may reflect the heterogeneity of study populations and settings, as studies were conducted in low-, middle-, and high-income countries over a span of almost 30 years. We attempted to reduce this heterogeneity by performing stratified analysis for major covariates, and by restricting the pooled analysis to patients with confirmed isoniazid mono-resistant pulmonary TB. We also used a more conservative meta-analytic method for pooled estimates and 95% CIs [@pmed.1000150-Hamza1]. Concerns over the heterogeneity from the variety of settings and populations are alleviated somewhat by the consistency of results observed in the stratified analysis and the meta-regression. This consistency provides greater confidence in the most important associations found.

A primary objective of this review was to compare the efficacy of different treatment regimens for INH mono-resistance. To accomplish this, we have analyzed the per-protocol results from each trial, using standardized microbiological definitions. All studies reviewed reported adverse events, dropouts, and defaulters separately, facilitating our approach. However, we did not include these outcomes because their definitions and ascertainment were not well standardized, potentially creating greater between-study variability. As well, differences between studies in providers and populations might have had greater influence on these outcomes than the differences in treatment response, potentially creating substantial bias with our analytic approach. Excluding patients who dropped out or defaulted would tend to underestimate treatment effects if these outcomes had been associated with the same treatment characteristics as failure or relapse. However, when this was examined, we found that the proportion that completed therapy was not significantly associated with any of the important treatment characteristics.

We did not study the effect of rifampin dose---largely most studies used the same dose (10--12 mg/kg), limiting power to detected associations of outcomes with dose. However some studies used 450 mg daily, at least initially, which may have been inadequate and contributed to the poor outcomes seen, leaving the optimal dose of rifampin still unresolved. We also could not distinguish between relapse of the same strain of *Mycobacterium tuberculosis* causing the initial infection versus re-infection with a new strain of the bacillus. In settings with high rates of ongoing exposure to *M. tuberculosis*, particularly if HIV seroprevalence is also high, a relatively high proportion of cases of recurrent TB following initial apparent cure may be due to re-infection [@pmed.1000150-Sonnenberg1]. However, very few patients had HIV co-infection in the studies reviewed, and in studies with longer follow-up, the great majority of relapses occurred in the first 1--2 y, with very few occurring in the third to fifth years. This suggests re-infection should have accounted for very few of the disease recurrences. Only four studies with 95 patients had less than 1 y follow-up; overall relapse rate in these studies was 10.5%, compared to 11.7% in all studies. Unequal follow-up should not have affected results, since duration of post-treatment follow-up was not associated with relapse or acquired drug resistance in multivariable analysis.

We restricted the research to three languages and three databases, raising the issue of adequacy of our search---germane since we found little evidence and no randomized trials assessing the current WHO regimen. A recent study found that 84% of published papers on TB were published in English, French, and Spanish [@pmed.1000150-Ramos1]. Nevertheless, we may have missed some studies because of the language restriction or the database restriction. However, when these findings were presented to expert groups at WHO, the International Union against Tuberculosis and Lung Disease, the Pan American Health Organization, and the American Thoracic Society, no additional relevant studies were identified by those attending. While somewhat reassuring, this cannot be considered systematic, nor evidence.

Given that 10%--20% of all patients receiving TB treatment in low- and middle-income countries require retreatment [@pmed.1000150-Mak1], it is obvious that this regimen plays a key role in the current DOTS strategy. Results with the current WHO retreatment regimen in the cohorts with pretreatment isoniazid resistance or mixed/unknown resistance were disturbingly poor. This may reflect inaccuracies in the performance of the drug sensitivity testing in these earlier studies, although high failure rates [@pmed.1000150-Mak1] and amplification of drug resistance have been documented under programme conditions [@pmed.1000150-Espinal1],[@pmed.1000150-Quy1]---supporting our findings. Hence, the most immediate needs identified by this review are to enhance access to accurate drug sensitivity testing for isoniazid and rifampin, and to redesign the recommended standardized retreatment regimen. This redesign should assume that rifampin will have been used throughout initial therapy and follow principles suggested by this review\'s pooled analysis for isoniazid mono-resistance. Intermittent therapy should be avoided in the initial intensive phase of the re-treatment regimen, at least four effective drugs should be used initially, and at least three effective drugs in the continuation phase. This review also provides support for prolonged use of pyrazinamide and use of streptomycin initially (or an alternative injectable drug in settings with high streptomycin resistance).

The long-term implication of this review is the dire need for evidence-based treatment of patients with drug resistance of all forms---in line with a recent call for research in drug resistant TB [@pmed.1000150-Espinal4]. Among new cases, the global weighted mean prevalence of multi-drug resistant TB is 2.9%, but 14.1% have other forms of drug resistance---of whom more than half have isoniazid resistance [@pmed.1000150-World3]. The need for trials in MDR TB [@pmed.1000150-Mitnick1] is inarguable. Although perhaps lacking the cachet of MDR, treatment of these other forms of drug resistance in new cases must also be given priority, for several reasons. First, these other forms of drug resistance are almost five times more common than MDR [@pmed.1000150-World3], accounting for 1.3 million new cases in 2008 (extrapolating from the estimated number of 9.2 million new cases [@pmed.1000150-World4]. In view of evidence that use of INH preventive therapy may result in increasing levels of INH resistance [@pmed.1000150-Cohen1],[@pmed.1000150-Balcells1], isoniazid resistance may further increase in countries responding to the "3 I\'s" initiative of WHO for prevention of HIV-TB [@pmed.1000150-World5]. Second, this review has demonstrated the profound weakness of the evidence base for treatment of most forms of drug resistance, including isoniazid resistance. Third, there is good evidence (see [@pmed.1000150-Menzies1]) that isoniazid and streptomycin resistance (each alone, or together) result in substantially worse treatment outcomes. Finally, this review and observational studies demonstrate that inadequate re-treatment regimens can result in high rates of failure and relapse with amplified drug resistance. Hence an effective regimen for the group that requires re-treatment could reduce generation of MDR.

A number of priorities for research can be identified from the findings of this review. These include the need for tailoring different regimens for various forms of resistance, the establishment of the minimum number of effective drugs used in the initial or continuation phases (to be balanced against tolerability and costs), the optimal dose of rifampin, the use and timing of intermittent administration, and use and duration of pyrazinamide or an injectable drug (including the utility of streptomycin in settings with high prevalence of streptomycin resistance). There is no doubt that such trials will be challenging, and large numbers of patients will be required. Hence multicenter and multinational randomized trials will be needed. This will require leadership, scientific direction, and funding at an international level [@pmed.1000150-Espinal4]. The potential availability of new drugs in the near future increases the need for adequate trials to avoid misuse of these new agents.

Conclusions {#s6}
===========

We conclude that there is little published evidence to support the continued use of the currently recommended retreatment regimen. There is an urgent need for a concerted international effort to substantially expand access to reliable drug sensitivity testing and to initiate randomized trials in patients with pretreatment drug resistance of all forms, particularly in previously treated patients. While awaiting results of these trials, the standardized retreatment regimen should be redesigned---at minimum to adequately treat patients with isoniazid resistance. In fact, the upcoming revised treatment guidelines from the WHO will consider these issues and provide some guidance on how to manage previously treated patients [@pmed.1000150-World6].
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